Diabetes

Diabetes:

Type 1 diabetes, also called juvenile diabetes, is an autoimmune disease that frequently presents itself from infancy to the late 30s For unknown reasons, the immune system sometimes launches an attack against the body’s own insulin-producing beta cells and destroys them. Nearly complete B-cell loss does characterize the final stages of the IDDM.

Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder of Insulin Resistance followed by Progressive and Inexorable β-cell dysfunction. The ultimate pathology is a failure of the pancreas to produce a sufficient amount of insulin to appropriately regulate glucose levels in the body. At the time of diagnosis, almost 50% of β-cell mass is lost.

” TYPE 1 AND TYPE 2 DIABETES RESULT ENTIRELY OR IN PART FROM INADEQUATE NUMBERS OF NORMALLY FUNCTIONING PANCREATIC BETA CELLS.

IT THEREFORE FOLLOWS THAT RESTORATION OF NORMAL BETA CELL MASS AND FUNCTION SHOULD BE A VIABLE SOLUTION. “

Mesenchymal stem cells facilitate regeneration of pancreatic beta cells probably recruitment of progenitors of insulin-producing beta cells. Mscs also ameliorate Insulin Resistance and exert immunomodulatory effects

How it is done

As a day care procedure 120 ml of Bone marrow and 200 ml of fat is aspirated and processed in a closed system for stem cells isolation. 2 ml volume having at least 2-4 million stem cells per kg body weight is injected either into

Allogenic umbilical cord derived MScs may be needed in few cases

What to expect

Type 1 diabetes

60 % pf patients show improvements
40% decrease in insulin requirement in first 3 months
60% dose decrement in the next 6 months
65% dose decrement in the next 9 months
55% dose decrement in the next 12 months
Simulated C peptide increased proportionately
60% patients could maintain HbA1c <7 HbA1c
One Patient Insulin free (at 15 months )

Type 2 diabetes

Overall, 80 % patients show significant response over 2 years
20% decrease in insulin req in the first 3 months
29% dose decrement AT 6 months
52% dose decrement AT 12 months
35% dose decrement AT 24 months
80% patients could maintain HbA1c between 6-7 months
12% of patients are able to discontinue insulin completely & only on oral drugs upto 2years
Insulin level basal and after meal improved by 60 % .
Stimulated C peptide levels increased proportionately and positively corelated with decrease in Insulin Requirement.

The website contains no medical advice. All statements and opinions provided by the website are for educational and informational purposes. ||The treatment centres associated with Revita lifesciences provide surgical procedure only and are not involved in use or manufacture of any investigational drug ||Revita does not claim that any application or potential application, using autologous stem cells are approved by the FDA. We do not claim that these procedures work for any listed nor unlisted condition, intended or implied.||It’s important for potential patients to do their own research based on the options we present so that one can make an informed decision. Any decision to participate in experimental protocol is completely voluntary ||

A to z of clinical and application based stem cell science under one roof